BTLA and Crohn disease: Modulating the HVEM–BTLA checkpoint could recalibrate T-cell responses in Crohn’s disease. HVEM-BTLA Checkpoint agonists or selective blockade of HVEM’s co-stimulatory ligand LIGHT might restore balance in the intestinal immune ecosystem.